A1M Pharma: ROSGardTM shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study
(WorldNews Sweden)

Read as The molecular targeted therapy PRRT, which is mainly used as a treatment for neuroendocrine tumours (NETs) that can spread to the gastrointestinal tract and the lungs, puts a heavy strain on the patient`s kidneys with the risk of serious kidney injuries as a consequence. This limits the maximum radiation dose that can be used, both in separate radiation treatments and in total. The symptoms of possible kidney injuries often do not appear until several months after the radiation therapy session. A1M Pharma has therefore conducted two preclinical studies with the candidate drug ROSGardTM that is being developed to be administered in connection with each radiation therapy session in...